Key statistics dashboard for Black Diamond Therapeutics, Inc. (BDTX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor.
Stock Data
| Price | $1.94 |
| Market Cap | $111M |
| Enterprise Value | $108.9M |
| Beta | 3.39 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.66 |
| Price / Book | 1.18 |
| P/S | 0.00 |
| EV/EBITDA | -2.67 |
| EV/Sales | 0.00 |
| EV/FCF | -3.40 |
| P/FCF | -3.53 |
| Earnings Yield | -38.24% |
| FCF Yield | -28.80% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -38.80% |
| Return on Assets | -34.04% |
| Return on Invested Capital | -45.91% |
| Return on Capital Employed | -47.54% |
Financial Health
| Current Ratio | 7.28 |
| Quick Ratio | 7.28 |
| Cash Ratio | 1.21 |
| Debt / Equity | 0.18 |
| Debt / Assets | 13.57% |
| Net Debt / EBITDA | 0.05 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.68 |
| Cash per share | 1.93 |
| FCF per share | -0.56 |
| Tangible Book Value per share | 1.68 |
| Dividend per share | 0.00 |
Related companies: AARD · ABEO · AVTX · CRBU · ENTA · FENC · FHTX
Explore sector: Healthcare · Biotechnology
More sections of BDTX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks